Dott. Gianpiero D. romano       PUBBLICAZIONI & Abstracts

1. G. Curigliano, A. Alcini, G. Flamini, A. Boninsegna, C. Ratto, M. Giustacchini, G. Romano, E. Alcini, R.M. Santella and A. Cittadini. “Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 cancer of smokers and nonsmokers”. Acta Medica Romana. 35, (1997), 18.


2.G. Romano , R Mancini, P. Fedele, G. Curigliano, G. Flamini, M. Giovagnoli, N. Malara, A. Boninsegna, A. Vecchione, R.M. Santella and A. Cittadini “Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers”. Anticancer Reserch. 17,(1997), 2827.I.F. 1.416


3. G. Flamini, G. Romano, G. Curigliano, A. Chiominto, G. Capelli, A. Boninsegna, C. Signorelli, L. Ventura, R.M. Santella and A. Cittadini. “4-aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study”. Carcinogenesis. 19, (1998), I.F. 4.543


4. A.Sgambato, G. Flamini, A. Boninsegna, G. Romano, A. Cittadini. “I biomarcatori nella valutazione del danno biologico da fattori ambientali in oncologia”. Nuove Prospettive in Terapia. 1, (1997), 7.


5.G. Romano , A. Sgambato, G. Flamini, A. Boninsegna, A. Ferro, C. Signorelli, A. Cittadini, V. La Gioia, D. Danese, A. Tricarico. “Applicazione di un nuovo approccio per la valutazione dei danni genetici associati al fumo di sigaretta” Giornale di Medicina Militare. 3-4, (1998),152.


6. A.Sgambato, G. Romano, G. Flamini, A. Cittadini. “Ruolo dei biomarcatori per la valutazione del danno biologico da rischio ambientale e professionale in oncologia”. Rivista Degli Infortuni e Delle Malattie Professionali. 2, (1998), 107.


7.G. Romano, G. Flamini, A. Sgambato, A. Boninsegna, V. La Gioia, G. Curigliano, V. La Gioia and A. Cittadini. “Evaluation of PAH-DNA adducts in exfoliated oral cells as indicator of carcinogen exposure and individual susceptibility.” Tumori. 84, suppl.1, (1998) 10.


8. G. Ferretti, G. Curigliano, G. Flamini, A. Sgambato, G. Romano, A. D’Addessi, and A. Cittadini. “Detection of p53 mutations by denaturing gradient gel electrophoresis in T1 bladder cancer biopsies and cells exfoliated in urine. A preliminary report”. Tumori. 84, suppl.1, (1998), 107.


9. A.Sgambato, L. Garagnani, B. Faraglia, M. Migaldi, G. Romano, G. Ferrari. G., and A. Cittadini . “Low p27kip1 expression correlates with tumor grade and disease recurrence in primary superficial bladder carcinomas. Tumori. 84, suppl.1, (1998), 107. 


10. A.Sgambato, G. Romano, A Cittadini. “Nuove metodiche di indagine per la valutazione dei danni da fumo”. Il tabacco. 7 (1999), 45.


11.G. Romano,  G. Flamini, A. Sgambato, A. Boninsegna, V. La Gioia, G. Capelli, G. Curigliano, G. Ferretti, R.M. Santella and A. Cittadini. “Evaluation of aromatic-DNA adducts in exfoliated oral cells by an immunohistochemical assay”. Cancer Epidemiology Biomarkers & Prevention. 8, (1999) .I.F. 3.966


12. Sgambato, M. Migaldi, B. Faraglia, L. Garagnani, G. Romano, C. De Gaetani, P. Ferrari, G. Capelli, G.P. Trentini, and A. Cittadini. “Loss of p27kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers”. Cancer Research. 59, (1999), 3245. I.F. 8.32


13. G. Maccauro, G. Romano, T. Nizegorodcew, A. Cittadini, E. De Santis. “Considerazioni sull’influenza della dimensione delle particelle nella patologia da detriti metallici e plastici”. Giornale italiano di Ortopedia e Traumatologia. In press.


14. R. Mancini, G. Romano, A. Sgambato, G. Flamini, M.R. Giovagnoli, A. Boninsegna, C. Carraro, A. Vecchione and A. Cittadini. “Polycyclic aromatic hydrocarbon-DNA adducts in cervical smears of smokers and nonsmokers”. Gynecologic Oncology. 75, (1999), 68.I.F. 2.2


15.G. Romano , L. Garagnani, A. Boninsegna, P. Ferrari, G. Flamini, C. De Gaetani, A. Sgambato, G. Ferrari, G. Curigliano, G. Ferretti, A. Cittadini and G.P. Trentini. “Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma”. Anticancer Research. 19, (1999), 4571. I.F. 1.416


16. A. Sgambato, C. Ratto, B. Faraglia, M. Merico, R. Ardito, G. Schinzari, G. Romano, A. Cittadini. “Reduced expression and altered subcellular localization of the cyclin-dependent kinase inibitor p27kip1 in human colon cancer”. Molecular Carcinogenesis. 26, (1999), 172. I.F. 3.265


17.G. Romano , A. Sgambato, R. Mancini, G. Flamini, M.R. Giovagnoli, G. Capelli, A. Boninsegna, A. Vecchione, A. Cittadini. “8-hydroxydeoxyguanosine in cervical cells DNA: correlation with HPV infection and grade of dysplasia”. Vienna, ECCO 10. European Journal of Cancer. 35, supp 4, (1999), 327.


18. A.Sgambato, M. Migaldi, B. Faraglia, L. Garagnani, G. Romano, C. De Gaetani, P. Ferrari, R. Ardito, G.P. Trentini, and A. Cittadini. “Loss of p27kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers”. European Journal of Cancer. 35, supp 4, (1999), 327.


19. A.Sgambato, C. Ratto, B. Faraglia,  G. Romano, G. Flamini. G., and A. Cittadini . “ Cytoplasmatic accumulation of the P277kip1 in colon cancer tissue compared with normal mucosa. Tumori. 85, suppl 1, (1999), 36.


20.G. Romano , G. Flamini, A.Sgambato, L, and A. Cittadini . “Effects of environmental factors on oxidative damage in oral cells. Tumori. 84, suppl.1, (1998), 58. 


21.G. Romano , A. Sgambato, M. Antimi,S. Milito, M. Minelli, G. Flamini, A. Boninsegna, A. Cittadini. “Oxidative Dna Damage Detection In Oral Cells: The Role Of Envoronmental Factors”. Annals Oncology. 11 supp 4 (2000), 12.


22.G. Curigliano, G. Ferretti, G. Flamini, A. Boninsegna, G. Romano, A. Sgambato, A. D’Addessi, D. Petrone, E. Alcini and A. Cittadini. “p53 mutation and 4-aminobiphenyl-DNA adducts in T1 transitional cell bladder carcinoma biopsies and exfoliated cells in urine”. Acta Medica Romana. 37, (1999), 479


23.G. Romano, A. Sgambato, A. Boninsegna, G. Flamini, G. Curigliano, et al. “A new approach for the evaluation of genotoxic damage and individual susceptibility in carcinogen exposed population”. Acta Medica Romana. 37, (1999), 581


24.G. Romano, A. Sgambato, R. Mancini, G. Capelli, M. Giovagnoli, G. Flamini, A. Boninsegna, A. Vecchione and A. Cittadini. “8-hydroxydeoxyguanosine in cervical cells: correlation with grade of dysplasia and HPV infection”. Carcinogenesis. 21, (2000), 1143.I.F. 4.543


25.G. Romano, A. Sgambato, G. Flamini, A. Boninsegna, S. Milito, R. Ardito and A. Cittadini. “Evaluation of 8-hydroxydeoxyguanosine in human oral cells: The importance of tobacco smoke and human environment. Anticancer Research. 20, (2000), 3804.I.F. 1.416


26.Covacci V, Torsello A, Palozza P, Sgambato A, Romano G, Boninsegna A, Cittadini A, Wolf FI. “DNA oxidative damage during differentiation of HL-60 human promyelocytic leukemia cells”. Chem Res Toxicol. 14 (2001) 1492. I.F. 3.179

27. Tartarone A, Romano G, Galasso R, Coccaro M, Cammarota A, Sgambato A, Bochicchio A. “Pulmonary blastoma after liver transplant: a case report”. Tumori. 88, (2002), 173.I.F. 0.49


28.Sgambato A, Campisi B, Zupa A, Bochicchio A, Romano G, Tartarone A, Galasso R, Traficante A, Cittadini A. “Glutathione S-transferase (GST) polymorphisms as risk factors for cancer in a highly homogeneous population from southern Italy”. Anticancer Res 22, (2002) 3647.I.F. 1.416


  1. 29.G. Romano, A. Sgambato A. Zupa A, B. Campisi, Bochicchio A, Tartarone A, Galasso R, Traficante A, Cittadini A. “Glutathione S transferase (GST) polymorphism as risk factors for cancer risk”. Annals of Oncology 13 supp. 5 (2002) 14.


  1. 30.AM. Bochicchio, G. Romano, A. Tartarone, A. Capobianco, P.Di Leo, M. Coccaro, M. Vigliotti, G. D’Arena, N. Di Renzo “Management of advanced bilio-pancreatic cancer”. Annals of Oncology 13 supp. 5 (2002) 200.


31.G. Romano, A. Sgambato et al. “Glutathione S transferase (GST) in higly homogeneous population from southern Italy”. Annals of Oncology vol. 13 (2002), 80.


  1. 32.AML Capobianco, G. Romano, et al. “Phase II study with vinorelbine an continuous infusion of 5FU in preatreated metastatic breast cancer patients”. Annals of Oncology vol. 13 (2002), 14.


33.M Coccaro, G. Romano, et al. “Dose-finding weekly docetaxel plus estramustine in patient with hormonoresistent metastatic prostate cancer”. Annals of Oncology vol. 13 (2002), 75.


34.ML. Vigliotti, G. D’Arena, G. Romano, et al. “A modified FND regimen in untreated follicular Non-Hodgkins lymphoma”. 7th meeting of the European Hematology Association. Firenze 6-9 giugno 2002. The Hematology Journal vol 3 (2002), 277.


35.ML. Vigliotti, G. D’Arena, G. Romano, et al. “Primary central nervous system lymphoma; analysis of 14 patients”. 7th meeting of the European Hematology Association. Firenze 6-9 giugno 2002. The Hematology Journal vol 3 (2002), 257


36.D’Arena G, Vigliotti M.L,  Romano G, Tartarone A, et al. “CD25 expression in B-cell chronic lymphocytic leukaemia”. 7th meeting of the European Hematology Association. Firenze 6-9 giugno 2002. The Hematology Journal vol 3 (2002), 242.


37.Vigliotti ML, Dell’Olio M, Romano G, Tartarone A, D’Arena G, Carella AM, Di Renzo N. “Primary gastric lymphoma (PGL) for stage I / II1 E: operative and conservative management in retrospective data from 71 cases”. Leukemia and Lymphoma 44, (2003), 1259.I.F. 1.257


38.Tartarone A, Romano G, Iodice G, Capobianco A, Di Renzo. “The predictive role of HER2-overexpression in early breast cancer”. Journal of Clincal Oncology 15, (2003), 3179. I.F. 8.53


39. Tartarone A, Romano G,  Galasso R. Iodice G, Di Renzo. “Should we continue high-dose therapy in metastatic breast cancer? A critical review of the published data” Bone Marrow Transplant. 31, (2003), 525. I.F. 2.554


40.A. Tartarone, G. Romano, M. Coccaro, G. Iodice, P. Di Leo, A.M. Bochicchio, A. Capobianco, C. Musto, M.L. Vigliotti, G. Mele, N. Di Renzo. “Cisplatin (CDDP) And Weekly Docetaxel (DCT) In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc). Phase II Study” Annals Oncology, Supp4, 14, iv20,2003.


41.G. Romano, A. Sgambato, A. Zupa, B. Campisi, A. Tartarone, A. Traficante, N. Di Renzo, A. Cittadini. “N-Acetyltransferase (NAT-2) And Glutathione S Trans-Ferase (GST) Polymorphisms As Risk Factors For Cancer In Southern Italian Patients”. Annals Oncology, Supp4, 14, iv83,2003.


42.M.L. Vigliotti , G. Mele , G. Romano, A. Tartarone, C. Musto et al. “Primary Non-Hodgkin Lymphoma Of The Breast (Pnhlb): A Report Of 7 Cases”. Annals Oncology, Supp4, 14, iv93,2003.


  1. 43.M.L. Vigliotti , G. Mele , G. Romano, A. Tartarone, M. Coccaro et al. “Primary central nervous system lymphoma in immunocompetent adults: analysis of a retrospective series of patients treated with idarubicin-containing regimen and radiotherapy”. Haematologica, Supp. 15, 80,2003.


44.G. Mele , M.L. Vigliotti , R. Matera , M. Coccaro, G. Romano et al. “A case of B-cell chronic lymphocitic leukaemia with osteolitic bone lesions”. Haematologica, Supp. 15, 156, 2003.


45.M.L. Vigliotti , A La Sala, G. Mele , G. Romano, A. Tartarone, M. Coccaro et al. “Efficacy and toxicity of modified-FND vs CHOP regimen in patients with previously untreated follicular lymphoma”. Haematologica, Supp. 15, 49, 2003.


46.A. Tartarone, G. Galucci, G Iodice, G. Romano et al. “Linezolid-induced bradycardia: a case report”. Int. Journal of Antimicrobial Agent 23,    412, 2004.   I.F. 1,95


47.A Tartarone, R. Matera, G. Romano et al. “Prevention of high dose melphalan-induced mucositis by cryotherapy (ice chips)”. Bone Marrow transplantation, 33, Supp 1, 312, 2004. 


48.G. Mele, A Tartarone, G.Romano et al. “Ph cromosome positive CML patient with suppurative periodontitis during treatment with imatinib. The Hematology Journal ”, 5, supp 2, 22, 2004.


49.A.Tartarone, G. Romano, A. Bochicchio et al. “Prevention of High dose melphalan-induced mucositis by cryotherapy in transplanted patients.”  ASCO proceedings, 23, 768, 8174, 2004.


50.G. Mele , C. Musto , R. Matera , M. Vigliotti, A. Tartarone,  G. Romano et al. “High-Dose of Epoietin Alfa in patients with LowRisk Myelodysplastic Syndromes: asingle institution experience”. Blood, Supp. 103, 2004.


51.A. Tartarone, R. Matera, G. Iodice, G.Romano et Al. “Management oh high dose melphalan induced oral mucositis: our experience”. Annals Oncology Supp 2, 15, 2004 .


52.G.Romano, A. Tartarone, A Bochicchio, et Al. “The impact of implanted venous access systems on normal daily activies in cancer patients”. Annals Oncology Supp 2, 15, 2004.



53.M. Coccaro, G.Romano A. Tartarone et Al. “Dose findings weekly docetaxel plus estramustine in patients with hormonoresistent metastatic prostate cancer”. Annals Oncology Supp 2, 15, 2004 .


54.A. Tartarone, R. Matera, G. Iodice, G. Romano et Al. “Management oh high dose melphalan induced oral mucositis: our experience”. Annals Oncology Supp 2, 15, 2004.



55.G. Mele, M. R Coccaro, R. Matera, G. Romano et al. “Acute myeloid leucemia M5A with co-expression of NK and Lymphoid antigens in blast cells and complex karyotype: a case report” Annals Oncology Supp 2, 15, 2004.


56.M. Vigliotti, A Tartarone, G. Romano et al. “Incidence and differential diagnosis with other neoplasm of lymph nodes sarcoidosis” Annals Oncology Supp 2, 15, 2004.



  1. 57.G. Iodice, V. Fusco, A Tartarone, et al G. Romano . “Radiation therapy and temozolamide as adjuvant therapy in patients with glioblastoma multiforme” Annals Oncology Supp 2, 15, 2004.


        58. A Tartarone, G. Romano, M. R Coccaro et al. “Our Experience wiyh cisplatin + weekly docetaxel in patients with advanced NSCLC”. Annals Oncology Supp 3, 15, 2004.


59.M. Caraglia, R. Addeo, R. Costanzo, G. Romano et al “Pegylated liposomal doxorubicin plus temozolamide is active in the treatment of brain metastases from solid tumours” Annals Oncology Supp 2, 15, 2004.



60.Tartarone A, Romano G, Iodice G, Di Renzo N, Ignomirelli O.    “Response to de Gramont regimen in small cell lung cancer : a case report.” Lung Cancer: 43: 375-6, 2004. I.F. 2.915


61.Vigliotti ML, Dell’Olio M, La Sala A, Romano G, Tartarone A, Mele G, Musto C, Carella AM, Di Renzo N. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy. Hematol  J.  5:453-5, 2004.


62.Tartarone A, Gallucci G, Cammarota A, Romano G, Ardito R, Di Renzo N Venous thromboembolism after high-dose chemotherapy in a patient with Hdgkin’s lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone (“Yasmine”). Bone Marrow Transplant. 35:103, 2005. I.F. 2.554


63.Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.   Eur Urol. 47:449-54, 2005.


64.Tartarone A, Matera R, Romano G, Vigliotti ML, Di Renzo N. Prevention of high-dose melphalan-induced mucositis by cryotherapy.     Leuk  Lymphoma 45:1489-90, 2004. I.F. 1.257


  1. 65.Tartarone A, Romano G,Iodice G, Capobianco A, Coccaro M, Bochicchio A, Di Leo P, Ardito R, Di Renzo N.  Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer: a phase II study. Tumori, 91:131-134, 2005. I.F. 0.49


  1. 66.Tartarone A, Wunder J, Romano G, Ardito R, Iodice G, Mazzuoli S, Barone L, Matera R, Di Renzo N. Role of parenteral nutrition in cancer patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation. ri, 91:237-240, 2005.  I.F. 0.49


67.Romano G, Tartarone A, G, Capobianco A, Coccaro M, Bochicchio A, Di Leo P, Ardito R, Di Renzo N.  The influence of externalized Groshong catheters of subcutaneously implanted ports on normal daily activies of cancer patients. Jounal Clinical Oncology, Vol 23, 16s, 8155.


68.Capobianco A, Coccaro M, Bochicchio A, Di Leo P, Ardito R, Romano G, Tartarone A, Di Renzo N. Importance of 5FU infusion duration and toxiciy during CMF administration in adjuvant setting of breast cancer. Annals of Oncology Vol 16, 7s,vii8.


69.Gallucci G, A, Coccaro M, Bochicchio A, Di Leo P, Ardito R,  Romano G,Tartarone A, Renzo N. Cardiotoxicity and 5FU continuous infusion: a mono istitutional experience. Annals of Oncology Vol 16, 7s,vii37


70.Bochicchio A, Romano G,Capobianco A, Tartarone A,Coccaro M, Di Leo P, Ardito R, Di Renzo N. et al. Xeloda and eloxatin as first line chemotherapy for advancrd colorectal cancer patients. Preliminary data about toxicity of a monoistitutional experience. Annals of Oncology Vol 16, 7s,vii44.


71.Tartarone A, Romano G, Ardito R, Capobianco A, Coccaro M, Bochicchio A, Di Leo P, Di Renzo N. Nutritional support with total parental nutrition in cancer patients trated with high dose chemotherapy followed by peripheral blood progenitor cells transplantation: our experence . Annals of Oncology Vol 16, 7s,vii67.


72.Ardito R, Tartarone A, Romano G, Coccaro M, Capobianco A, , Bochicchio A, Di Leo P, et al. Stevens-Johnson Syndrome To Valaciclovir In A Patient With A Non-Hodgkin Lymphoma. Annals of Oncology Vol 17, 9s,ix209.


  1. 73.Tartarone A, Romano G, Ardito R, Barone L, Guariglia R, Coccaro A, Bochicchio A, Di Leo P, et al. Our Experience With Transdermal Therapeutic System Fentanyl In The Pain Management Of High Dose Chemotherapy Associated Oral Mucositis. Annals of Oncology Vol 17, 9s,ix299.


  1. 74.Chiuri VE, Leo S, Ciccarese M, Accettura C, et al., Romano G, et al. Use Of Prulifloxacin In Addition To Granulocyte-Colony-Stimulating-Factor (GCSF) In Order To Prevent Neutropenia Complications In Cancer Patients. Annals of Oncology Vol 20, 8s, viii44.


  1. 75.Romano G, Gnoni A, Leo S, Musca F, Ciccarese M, Cairo G, et al. Is the planned dose intensity of folfox or xelod administered in colon cancer patients in adjuvant settings? a retrospective analysis. Annals of Oncology Vol 21, 6s, vi64.


  1. 76. Romano G, Gnoni A, Leo S, Musca F, Ciccarese M, Cairo G, et al. How often is adjuvant xelox discntinued for toxicity among colon cancer patients in adjuvant setting? Tumori Vol 10, s10, a18.


  1. 77. Romano G, Lorusso V. Farmaci biomolecolari nel carcinoma polmonare non piccole cellule. Oncologia Toracica. Ed  Ragusa, 2007.


  1. 78. Forcignanò R, Ciccarese M, Romano G, Chiuri V, et al. Evaluation of efficacy and compliance with two different bisphosphonates in  hormone-sensitive postmenopausal patients with breast cancer treated with adiuvant  Aromatase  Inhibitors (AIs): comparison between Alendronate orally once a week vs  Zoledronate i.v. yearly. Tumori Vol 10, s28, b28.


  1. 79. Romano G, Colonna M, Gnoni A, Leo S, Forcignanò R, Nucco C, et al. “Dose Intensity and toxicity of adjuvant Xelox and Folfox in over 65 years colon cancer patients. Annals of Oncology Vol 22, 5s, v119.


  1. 80. Domenico Galetta, Salvatore Pisconti, Saverio Cinieri, Vittorio Gebbia, Giovanni Luigi Pappagallo, Nicola Borsellino, Angelo Nacci, Michele Montrone, Giuseppe Palomba, Alessandro Morabito, Giampiero Romano, et al. “Induction pemetrexed and cisplatin followed by maintenance pemetrexed vs carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab: multicenter randomized phase iii study in patients with advanced non-squamous non small-cell lung cancer (NSCLC). preliminary data of a quality of life oriented phase III trial of the GOIM (gruppo oncologico italia meridionale).” Journal of Thoracic Oncology  Vol 6, 2S, S1200.


  1. 81. Romano G, et al. Casi Clinici. Sharing Best Practice in Oncologia. Monografia Punto Effe 2011.


  1. 82. Lorusso V, Saracino V, Romano G, Nacci A, et al. “ Erlotinib in the real life: Retrospective results in NSCLC in two italian centers. Clin Oncol 30, 2012 (suppl; abstr e18048).


  1. 83. Lorusso V, Marech I, Saracino V, Romano G, Leo S, Gnoni A. “Erlotinib in patients with NSCLC: retrospective results of an italian center.” Tumori Vol 13, s88, d29, 2013.


  1. 84. Romano G, Cocciolo A, Vasta I, Gnoni A, Licchetta A et al. “Lung adenocarcinoma with EML4-ALK traslocation and ovarian teratoma in a 20-year old woman. A case report.”. Journal of Thoracic Oncology  Vol 8, 2S, S1298., 2013 .


  1. 85. Ciccarese M, Accettura C,  Giotta F, Leo S, Forcignanò R, Scavelli C, Romano G, et al. “Denosumab for bone metastases in advanced cancer”. Tumori Vol 15, s87, f19, 2014.


  1. 86. Santo A, Roca E, La Russa F,  Grossi F,  Genova C, Favaretto A.G. , Sibau A,  Follador A, Bearz A,  Romano G, et al. “Maintenence with Lanreotide in SCLC patients expressing Somatostatine Receptors after response ti first line therapy”.  Abs. P2.07-011,  16th  World Conference on Lung Cancer.


  1. 87. Normanno N, Morabito A, Novello S, Cortinovis D, Migliorino MR, Pinto C, Romano G,...Crino’ L. Circulating free tumor DNA as a surrogate for determination of EGFR startus: the italian experience within the ASSES study. Annals of Oncology Vol 26, 6s, vi74.


  1. 88. L'approccio terapeutico di II linea al paziente con NSCLC: presente e futuro. Editree editore. 2016


  1. 89. Benjamin Besse, Sylvestre Le Moulec, Julien Mazieres, Damien Pouessel, Istvan Albert, Giampiero Romano et al. “TEDOPI vs standard treatment as 2nd or 3rd line in HLA-A2 positive advanced nsclc patients in a phase 3, randomized trial: ATALANTE-1. Journal of Thoracic Oncology • Volume 12 Issue S1, s569,  January 2017 .


  1. 90. Francesco Grossi, Agnese Montanino, Maria Rita Migliorino, Antonio Santo, Michele De Tursi, Angelo Delmonte, Fabiana Vitiello, Manlio Mencoboni, Vito D’Alessandro, Giampiero Romano et al. “Observational study on prolonged disease stabilization in advanced nsclc EGFR wt/unknown patients treated with Erlotinib in second line. Journal of Thoracic Oncology • Volume 12 Issue S1, s348, January 2017.


  1. 91.    Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol 2017 May;143(5):783-791. doi: 10.1007/s00432-016-2326-x. Epub 2017 Feb 18.



  1. 92. S. Pilotto, E. Bria, D. Galetta, F. Grossi, G. Fasola, G. Romano, L. Bonanno et al. Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial. Journal of Thoracic Oncology • Volume 12 Issue 11, S2, P1801,  November 2017 .


  1. 93. E. Capelletto, M. Migliorino, A. Morabito, R. Chiari, F. Grossi, M. Tiseo, F. Di Costanzo, A. Delmonte, G. Romano, A Misino et al., “Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience.  P1.01-73 19th World Conference on Lung Cancer IASLC. Toronto.


  1. 94.  Filippo De Marinis, Massimo Barberis, Vito Barbieri, Alfonso Marchianò, Stefano Gasparini, Maria Rita Migliorino, Giampiero Romano, Francesca Spinnato, Fabiana Vitiello & Cesare Gridelli. “ Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice”. Expert Review of Respiratory Medicine, Vol.13, 2019. DOI: 10.1080/17476348.2019.1569517


  1. 95. Enriqueta Felip, Giuseppe Giaccone, Rafal Dziadziuszko, Fabrice Denis, Teresa Moran, Didier Debieuvre, Manuel Cobo, Domenico Galetta, François Roger Vanel, Giampiero Romano, “ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. “ J Clin Oncol 37, 2019 (suppl; abstr TPS9121).


  1. 96.    Enrica Capelletto, MariaRita Migliorino, Alessandro Morabito, Rita Chiari, FrancescoGrossi, fMarcelloTiseo, Francesco DiCostanzo, AngeloDelmonte ,Gianpiero Romano et al. Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer Volume 134, August 2019, Pages 210-217.


  1. 97.    Enrica Capelletto, Giorgia Osman, Alessandro Morabito, Rita Chiari, MariaRita Migliorino,  Francesco Grossi, fMarcello Tiseo, Francesco Di Costanzo, AngeloDelmonte ,Gianpiero Romano et al. NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy. P2.04-84 2019 World Conference on Lung Cancer


  1. 98.    Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, et al. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. Lung Cancer 2019 Aug;134:121-126.  doi: 10.1016/j.lungcan.2019.06.011. Epub 2019 Jun 11.


  1. 99.    Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, et al. Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. Cancers (Basel). 2019 Sep 25;11(10):1431. doi: 10.3390/cancers11101431.


  1. 100.    E. Capelletto ,  A. Morabito ,  F. Grossi ,  F. Di Costanzo , G. Osman ,  R. Chiari , P. Bordi ,  V. Scotti ,  G. Romano et al. 1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial. Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz260.090,


  1. 101.    E. Felip,  B. Besse,  R. Dziadziuszko,  M. Cobo Dols, F. Denis,  M. García-Campelo, D. Debieuvre,  M. Moran Bueno ,  A. Madroszyk Flandin ,  P. Masson , C. Chouaid ,  P. Lianes ,  F. Cappuzzo ,  A. Delmonte , G. Robinet ,  G. Romano et al. 1592TiP - ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz260.114.


  1. 102.    Maria Lucia Realea, Rita Chiarib, Marcello Tiseoc, Fabiana Vitiellod, Fausto Barbierie, Diego Cortinovisf, Giovanni Luca Ceresolig, Giovanna Finocchiaroh, Gianpiero Diego Romanoi, et al. Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer. 2019 Dec 16;140:71-79. doi: 10.1016/j.lungcan.2019.12.006.


  1. 103.     Editta Baldini, Alice Lunghi, Enrico Cortesi, Daniele Turci, Diego Signorellid, Valeria Stati, Barbara Melottif, Biagio Ricciuti, Antonio Frassoldati, Giampiero Romano, et al. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer, Volume 140, Febb 2020. Pages 59–64.


  1. 104.     G. Giaccone, E. Felip, M. Cobo, R. Garcia Campelo, F. Denis, E. Quoix, A. Madroszyk, D. Debieuvre, W. Hilgers, T. Moran, D. Galetta, G.D. Romano et al.  Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial. Annals of Oncology Vol. 31, Supp. 4, S814-S815, September 01, 2020 DOI:https://doi.org/10.1016/j.annonc.2020.08.1574.


  1. 105.  B. Besse, M.R. Garcia Campelo, M.A. Cobo Dols, E. Quoix, A. Madroszyk, E. Felip, F. Cappuzzo, F. Denis, W. Hilgers, G. Romano et al. Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial.. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741


  1. 106.   Silipigni S., Olmetto E., Leonetti A., Adamo V., Romano G.,  et al. BE-PACIFIC (Italian observational study on patient management strategies in real-world Clinical practIce for patIents with locally advanced (stage III) NSCLC: first Interim Analysis on the diagnostic work-up. Tumori Journal, v106, 2s, Oct 2020 , A04, pag 5.


  1. 107.     Leo S.1 Nestola C., Accogli G., Leucci M., Calogiuri M., Cairo G., Romano G. et al.  Evaluation of Chemobrain in Chemotherapy and Immunotherapy treated oncogeriatric patients: could the olfactory impairment be a biomarker? Tumori Journal, v106, 2s, Oct 2020, T22, pag 187.


  1. 108.    Ragusa A, Romano P, Lenucci MS, Civino E, Vergara D, Pitotti E, Neglia C, Distante A, Romano GD, et al. Differential Glycosylation Levels in Saliva from Patients with Lung or Breast Cancer: A Preliminary Assessment for Early Diagnostic Purposes. Metabolites. 2021 Aug 24;11(9):566. doi: 10.3390/metabo11090566.


  1. 109.    Benjamin Besse, Rosario Garcia Campelo, Manuel Cobo-Dols, Elisabeth Anne Quoix, Anne Madroszyk, Enriqueta Felip, Federico Cappuzzo, Fabrice Denis, Werner Hilgers, Giampiero Romano et al. Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial. J Clin Oncol 40, 2022 (suppl 16; abstr 9094). 10.1200/JCO.2022.40.16_suppl.9094